Clinical Trials Logo
  1. Home
  2. Hepatitis C Infection
  3. NCT02076100

Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)

Hepatitis C Infection Clinical Trial

Official title:
A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects With Hepatitis C Infection

Clinical Trial Summary

This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection. Successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tolerated dose of Ruzasvir. Part I will be for participants with hepatitis C virus (HCV) genotype 3 (GT3) and will run first: Part II will be for participants with HCV genotype 1a (GT1a), and Part III will be for participants with HCV genotype 2b (GT2b). Parts II and III may run concurrently. The primary study hypothesis is that a safe and tolerable dose of Ruzasvir that reduces viral load will be found to support further clinical investigation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02076100
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 1
Start date March 27, 2014
Completion date November 15, 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT01771653 - Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection N/A
Recruiting NCT03601546 - Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
Completed NCT02362217 - A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination Phase 1
Completed NCT00513461 - Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection Phase 2
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT02247401 - Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt Phase 3
Completed NCT02582632 - A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults Phase 3
Terminated NCT01532908 - Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C Phase 2
Recruiting NCT01754961 - Effects of Vitamin D on Inflammation in Liver Disease Phase 2
Terminated NCT01465516 - Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir N/A
Completed NCT01265511 - Study of SCY-635, Pegasys and Copegus in Hepatitis C Phase 2
Completed NCT04042740 - Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Phase 2
Not yet recruiting NCT05601518 - Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
Terminated NCT02429583 - Effects of Persistent Innate Immune Activation on Vaccine Efficacy Phase 4
Not yet recruiting NCT05506475 - Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
Withdrawn NCT02112630 - Boceprevir in End Stage Renal Disease (ESRD) N/A
Terminated NCT01841502 - Interaction Between Paroxetine and Telaprevir Phase 2
Completed NCT01803308 - A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection Phase 1
Terminated NCT01560468 - Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection Phase 1
Active, not recruiting NCT02772003 - DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Phase 1